L
Lawrence D. Kaplan
Researcher at University of California, San Francisco
Publications - 147
Citations - 7076
Lawrence D. Kaplan is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lymphoma & Non-Hodgkin's lymphoma. The author has an hindex of 42, co-authored 139 publications receiving 6564 citations. Previous affiliations of Lawrence D. Kaplan include San Francisco General Hospital & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
Donald W. Northfelt,B. J. Dezube,J A Thommes,B J Miller,Margaret A. Fischl,A Friedman-Kien,Lawrence D. Kaplan,C Du Mond,R D Mamelok,David H. Henry +9 more
TL;DR: Pegylated-liposomal doxorubicin is more effective and less toxic than the standard combination chemotherapy regimen ABV for treatment of AIDS-KS.
Journal ArticleDOI
AIDS-Associated Non-Hodgkin's Lymphoma in San Francisco
Lawrence D. Kaplan,Donald I. Abrams,Ellen Feigal,Michael S. McGrath,James O. Kahn,Padraic Neville,John L. Ziegler,Paul A. Volberding +7 more
TL;DR: Survival was shorter among patients who received higher doses of cyclophosphamide (greater than 1 g/m2), including those treated with the COMET-A regimen, and the most important predictor of survival was the total number of CD4-positive lymphocytes.
Journal ArticleDOI
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
Lawrence D. Kaplan,Jeannette Y. Lee,Richard F. Ambinder,Joseph A. Sparano,Ethel Cesarman,Amy Chadburn,Alexandra M. Levine,David T. Scadden +7 more
TL;DR: The addition of rituximab to CHOP in patients with HIV-NHL may be associated with improved tumor responses, however, these benefits may be offset by an increase in infectious deaths, particularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3).
Journal ArticleDOI
Doxorubicin Encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS-Related Kaposi's Sarcoma
Donald W. Northfelt,Donald W. Northfelt,Francis J. Martin,Paul A. Volberding,Paul A. Volberding,Julie Russell,Julie Russell,Mary S. Newman,Michael Amantea,Lawrence D. Kaplan,Lawrence D. Kaplan +10 more
TL;DR: Encapsulation in liposomes containing surface‐bound PEG significantly limits the distribution and elimination of doxorubicin, results in greater accumulation of the drug in KS lesions 72 hours after dosing than does standard dox orubic in, and may improve drug efficacy and therapeutic index in the treatment of AIDS‐KS.
Journal ArticleDOI
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)
James L. Rubenstein,Eric D. Hsi,Jeffrey L. Johnson,Sin-Ho Jung,Megan O. Nakashima,Barbara Grant,Bruce D. Cheson,Lawrence D. Kaplan +7 more
TL;DR: It is demonstrated for the first time to the authors' knowledge that dose-intensive consolidation for PCNSL is feasible in the multicenter setting and yields rates of PFS and OS at least comparable to those of regimens involving WBRT.